Pharmaceutical composition and method for the transdermal delivery of magnesium

• US 20050196434A1
• Filed: 01/19/2005
• Published: 09/08/2005
• Est. Priority Date: 03/04/2004
• Status: Abandoned Application

• Current Assignee: Barbara T. Brierre
• Original Assignee: Barbara T. Brierre
• Inventors: Brierre, Barbara T.
• Application Number:
  US11/039,507
• Publication Number:
  US 20050196434A1
• Time in Patent Office: Days
• US Class Current: 424/449
• CPC Class Codes: A61K 31/197 the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid carnitine A61K31/205
• CPC Class Codes: A61K 31/4415 Pyridoxine, i.e. Vitamin B6 pyridoxal phosphate A61K31/675
• CPC Class Codes: A61K 31/455 Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
• CPC Class Codes: A61K 31/51 Thiamines, e.g. vitamin B1
• CPC Class Codes: A61K 31/525 Isoalloxazines, e.g. riboflavins, vitamin B2
• CPC Class Codes: A61K 31/714 Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
• CPC Class Codes: A61K 33/06 Aluminium, calcium or magnesium; Compounds thereof , e.g. clay
• CPC Class Codes: A61K 33/30 Zinc; Compounds thereof
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61K 9/0014 Skin, i.e. galenical aspects of topical compositions non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00
• CPC Class Codes: A61K 9/06 Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels composition of ointments, creams or gels A61K47/00

Abstract

The present invention relates to a method and transdermal pharmaceutical composition for preventing magnesium deficiency or imbalances associated with magnesium deficiency including diabetes, hypertension, high cholesterol, cardiac arrhythmias, acute myocardial infarction, arteriosclerosis, atherosclerosis, preeclampsia, dysautonomia, mitral valve prolapse, asthma, constipation, irritable bowel syndrome, migraines, muscle spasms and cramping, premenstrual syndrome, osteoporosis, kidney stones, chronic fatigue syndrome, and fibromyalgia. The transdermal pharmaceutical composition includes a therapeutically effective amount of a pharmaceutically acceptable salt of magnesium and a pharmaceutically acceptable carrier. A therapeutically effective amount of a pharmaceutically acceptable salt of zinc a vitamin such as B-complex vitamin, a carotenoid, a mineral, or a combination thereof may also be included in the transdermal pharmaceutical composition. A therapeutically effective amount of progesterone may also be included in the transdermal pharmaceutical composition. The transdermal pharmaceutical composition may be topically administered to prevent magnesium deficiency or imbalances caused by magnesium deficiency.

Claims

1. A transdermal pharmaceutical composition for preventing magnesium deficiency or imbalances caused by magnesium deficiency comprising:

a therapeutically effective amount of a pharmaceutically acceptable salt of magnesium,

a therapeutically effective amount of a vitamin selected from the group consisting of vitamin B₆, vitamin B₁₂, vitamin B₉, vitamin B₃, vitamin B₅, vitamin B₂, vitamin B₁, and any combination thereof, and

a pharmaceutically acceptable carrier.

2. The transdermal pharmaceutical composition according to claim 1, wherein said pharmaceutically acceptable salt of magnesium is magnesium chloride.

3. The transdermal pharmaceutical composition according to claim 2, wherein said therapeutically effective amount of magnesium chloride is in the range of 5% to 15% of a total weight of said composition.

4. The transdermal pharmaceutical composition according to claim 3, wherein said therapeutically effective amount of magnesium chloride is about 10% of the total weight of said composition.

5. The transdermal pharmaceutical composition according to claim 1, further comprising a therapeutically effective amount of a pharmaceutically acceptable salt of zinc.

6. The transdermal pharmaceutical composition according to claim 5, wherein said pharmaceutically acceptable salt of zinc is zinc chloride.

7. The transdermal pharmaceutical composition according to claim 1, wherein said therapeutically effective amount of vitamin B₆ is in the range of 2% to 8% of a total weight of said composition.

8. The transdermal pharmaceutical composition according to claim 7, wherein said therapeutically effective amount of vitamin B₆ is about 5% of the total weight of said composition.

9. The transdermal pharmaceutical composition according to claim 1, wherein said therapeutically effective amount of vitamin B₁₂ is in the range of 0.0025% to 0.005% of a total weight of said composition.

10. The transdermal pharmaceutical composition according to claim 9, wherein said therapeutically effective amount of vitamin B₁₂ is about 0.005% of the total weight of said composition.

11. The transdermal pharmaceutical composition according to claim 1, wherein said therapeutically effective amount of vitamin B₉ is in the range of 0.04% to 0.12% of a total weight of said composition.

12. The transdermal pharmaceutical composition according to claim 11, wherein said therapeutically effective amount of vitamin B₉ is about 0.04% of the total weight of said composition.

13. The transdermal pharmaceutical composition according to claim 1, wherein said therapeutically effective amount of vitamin B₃ is in the range of 2.5% to 30% of a total weight of said composition.

14. The transdermal pharmaceutical composition according to claim 13, wherein said therapeutically effective amount of vitamin B₃ is about 20% of the total weight of said composition.

15. The transdermal pharmaceutical composition according to claim 1, wherein said therapeutically effective amount of vitamin B₅ is in the range of 2.5% to 50% of a total weight of said composition.

16. The transdermal pharmaceutical composition according to claim 15, wherein said therapeutically effective amount of vitamin B₅ is about 20% of the total weight of said composition.

17. The transdermal pharmaceutical composition according to claim 1, wherein said therapeutically effective amount of vitamin B₂ is in the range of 2.5% to 30% of a total weight of said composition.

18. The transdermal pharmaceutical composition according to claim 17, wherein said therapeutically effective amount of vitamin B₂ is about 20% of the total weight of said composition.

19. The transdermal pharmaceutical composition according to claim 1, wherein said therapeutically effective amount of vitamin B₁ is in the range of 2.5% to 30% of a total weight of said composition.

20. The transdermal pharmaceutical composition according to claim 19, wherein said therapeutically effective amount of vitamin B₁ is about 10% of the total weight of said composition.

21. The transdermal pharmaceutical composition according to claim 1, wherein said pharmaceutically acceptable carrier comprises a pluronic lecithin organogel.

23. The transdermal pharmaceutical composition according to claim 1, wherein said imbalances caused by magnesium deficiency are selected from the group consisting of diabetes, hypertension, high cholesterol, cardiac arrhythmias, acute myocardial infarction, arteriosclerosis, atherosclerosis, preeclampsia, dysautonomia, mitral valve prolapse, asthma, constipation, irritable bowel syndrome, migraines, muscle spasms and cramping, premenstrual syndrome, osteoporosis, kidney stones, chronic fatigue syndrome, and fibromyalgia.

24. The transdermal pharmaceutical composition according to claim 1, further comprising a therapeutically effective amount of a progesterone.

25. The transdermal pharmaceutical composition according to claim 24, wherein said therapeutically effective amount of progesterone is in the range of 1% to 2% of the total weight of said composition.

26. The transdermal pharmaceutical composition according to claim 25, wherein said therapeutically effective amount of progesterone is about 2% of the total weight of said composition.

27. The transdermal pharmaceutical composition according to claim 1, further comprising a therapeutically effective amount of lycopene.

28. The transdermal pharmaceutical composition according to claim 1, further comprising a therapeutically effective amount of lutein.

29. The transdermal pharmaceutical composition according to claim 1, further comprising a therapeutically effective amount of selenium.

22. The transdermal pharmaceutical composition according to claim 22, wherein said pluronic lecithin organogel comprises a mixture of a soy lecithin/isopropyl palmitate and a pluronic F127 gel.

30. A method of preventing magnesium deficiency or imbalances caused by magnesium deficiency comprising the steps of topically administering a transdermal pharmaceutical composition comprising:

a therapeutically effective amount of a pharmaceutically acceptable salt of magnesium,

a therapeutically effective amount of a vitamin selected from the group consisting of vitamin B₆, vitamin B₁₂, vitamin B₉, vitamin B₃, vitamin B₅, vitamin B₂, vitamin B₁, and any combination thereof; and

a pharmaceutically acceptable carrier.

31. The method according to claim 30, wherein said pharmaceutically acceptable salt of magnesium is magnesium chloride.

32. The method according to claim 31, wherein said therapeutically effective amount of magnesium chloride is in the range of 5% to 15% of a total weight of said composition.

33. The method according to claim 32, wherein said therapeutically effective amount of magnesium chloride is about 10% of the total weight of said composition.

34. The method according to claim 30, wherein said transdermal pharmaceutical composition further comprises a pharmaceutical acceptable salt of zinc.

35. The method according to claim 34, wherein said pharmaceutical acceptable salt of zinc is zinc chloride.

36. The method according to claim 30, wherein said therapeutically effective amount of vitamin B₆ is in the range of 2% to 8% of a total weight of said composition.

37. The method according to claim 36, wherein said therapeutically effective amount of vitamin B₆ is about 5% of the total weight of said composition.

38. The method according to claim 30, wherein said therapeutically effective amount of vitamin B₁₂ is in the range of 0.0025% to 0.005% of a total weight of said composition.

39. The method according to claim 38, wherein said therapeutically effective amount of vitamin B₁₂ is about 0.005% of the total weight of said composition.

40. The method according to claim 30, wherein said therapeutically effective amount of vitamin B₉ is in the range of 0.04% to 0.12% of a total weight of said composition.

41. The method according to claim 40, wherein said therapeutically effective amount of vitamin B₉ is about 0.04% of the total weight of said composition.

42. The method according to claim 30, wherein said therapeutically effective amount of vitamin B₃ is in the range of 2.5% to 30% of a total weight of said composition.

43. The method according to claim 42, wherein said therapeutically effective amount of vitamin B₃ is about 20% of the total weight of said composition.

44. The method according to claim 30, wherein said therapeutically effective amount of vitamin B₅ is in the range of 2.5% to 50% of a total weight of said composition.

45. The method according to claim 44, wherein said therapeutically effective amount of vitamin B₅ is about 20% of the total weight of said composition.

46. The method according to claim 30, wherein said therapeutically effective amount of vitamin B₂ is in the range of 2.5% to 30% of a total weight of said composition.

47. The method according to claim 46, wherein said therapeutically effective amount of vitamin B₂ is about 20% of the total weight of said composition.

48. The method according to claim 30, wherein said therapeutically effective amount of vitamin B₁ is in the range of 2.5% to 30% of a total weight of said composition.

49. The method according to claim 48, wherein said therapeutically effective amount of vitamin B₁ is about 10% of the total weight of said composition.

50. The method according to claim 30, wherein said transdermal pharmaceutical composition further comprises a therapeutically effective amount of a progesterone.

51. The method according to claim 50, wherein said therapeutically effective amount of progesterone is in the range of 1% to 2% of a total weight of said composition.

52. The method according to claim 51, wherein said therapeutically effective amount of progesterone is about 2% of the total weight of said composition.

53. The method according to claim 30, wherein said pharmaceutically acceptable carrier comprises a pluronic lecithin organogel.

54. The method according to claim 53, wherein said pluronic lecithin organogel comprises a mixture of a soy lecithin/isopropyl palmitate and a pluronic F127 gel.

55. The method according to claim 30, wherein said imbalances are selected from the group consisting of diabetes, hypertension, high cholesterol, cardiac arrhythmias, acute myocardial infarction, arteriosclerosis, atherosclerosis, preeclampsia, dysautonomia, mitral valve prolapse, asthma, constipation, irritable bowel syndrome, migraines, muscle spasms and cramping, premenstrual syndrome, osteoporosis, kidney stones, chronic fatigue syndrome, and fibromyalgia.

56. The method according to claim 30, wherein said transdermal pharmaceutical composition further comprises a therapeutically effective amount of lycopene.

57. The method according to claim 30, wherein said transdermal pharmaceutical composition further comprises a therapeutically effective amount of lutein.

58. The method according to claim 30, wherein said transdermal pharmaceutical composition further comprises a therapeutically effective amount of selenium.